Novavax vaccine – Functions, features, and usage eligibility

Novavax vaccine – Functions, features, and usage eligibility
health

As the world continues to combat the relentless COVID-19 pandemic, an array of vaccines has emerged as potent weapons against the virus. Vaccines are crucial for preventing diseases, protecting vulnerable individuals, and achieving herd immunity. Among them, the Novavax COVID-19 vaccine has garnered attention for its unique attributes. Therefore, it’s essential to be well-informed about the vaccine. Here are some key aspects of the Novavax vaccine, including how it works, its characteristics, possible side effects, and eligibility.

Novavax’s study of the COVID-19 vaccine for children

In the global campaign against the COVID-19 pandemic,  there has been a significant emphasis on expanding vaccination efforts to encompass a wider age range. After receiving emergency use authorization in the country for adults, Novavax recognized the importance of extending this protection to younger individuals. Vaccinating adolescents not only bolsters their individual immunity but also plays a vital role in reducing   overall virus transmission and protecting vulnerable communities. In response to this demand, Novavax, a prominent player in vaccine research and development, expanded its COVID-19 vaccine study to include children between the ages of 12 and 17. Its recent testing and data collection are attuned with the established regulatory directives and guidelines provided by agencies like the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Is Novavax vaccine suitable for children aged 12 to 17?
The simple answer is yes. The recent 2022 FDA authorization underscores the vaccine’s suitability for adolescents and young adults. The studies and research by Novavax ensured comprehensive protection against the virus across all age groups.

How does Novavax vaccine work?
Here is a step-by-step process of how the Novavax vaccine works to protect oneself against COVID-19 virus:

  • Protein production
    Novavax’s vaccine does not contain the live virus that causes COVID-19. Instead, it contains a lab-made piece of the spike protein found on the virus’s surface. This spike protein is harmless on its own.
  • Immune response
    When one receives the vaccine, one’s immune system recognizes the spike protein as a foreign substance and starts producing antibodies against it. These antibodies and T-cells attack and destroy the potential threat.
  • Memory cells
    The vaccine also stimulates the creation of memory cells in one’s immune system. These cells remember how to recognize and fight the spike protein. They are like the body’s defense plan in case one encounters the real virus in the future.
  • Protection
    If one is exposed to the actual COVID-19 virus later on, one’s immune system will recognize the spike protein on the virus’s surface and quickly produce antibodies to attack it. This rapid recognition and response can either prevent one from getting sick or make the illness much milder.

In essence, Novavax’s vaccine trains one’s immune system to recognize and fight the COVID-19 virus without making one sick from the virus itself. It’s a way to prepare one’s body’s defenses to respond effectively if one is exposed to the real virus.

How is Novavax different from other Covid-19 vaccines?
Novavax is a COVID-19 vaccine that has garnered attention for its unique characteristics and differences from other vaccines. Here’s how it differs from its counterparts:

  • Technology
    Novavax vaccine employs a protein subunit vaccine technology. It uses a harmless piece of the SARS-CoV-2 virus, the spike protein, to stimulate an immune response. The spike protein is crafted in a laboratory as a nanoparticulate. In contrast, vaccines like that use Messenger RNA (mRNA) technology, which provides a blueprint or genetic code to instruct cells on how to manufacture a specific spike protein.
  • Time-tested manufacturing method
    Novavax’s method is more in line with traditional vaccine development, akin to the approach used for vaccines like influenza. The familiarity of Novavax’s time-tested method may instill confidence in some people regarding the safety and reliability of its manufacturing processes.
  • Storage requirements
    Novavax’s vaccine typically has less demanding storage requirements. It can be kept at regular refrigeration temperatures, eliminating the need for ultra-cold storage facilities. This feature enhances the ease of administration and distribution, particularly in regions with limited access to specialized storage infrastructure. In contrast, mRNA vaccines usually require ultra-cold storage at temperatures well below freezing. This difference may reduce logistical challenges and costs associated with maintaining vaccines.
  • Effectiveness
    The efficacy of Novavax’s COVID-19 vaccine can vary depending on the specific traits of the virus it encounters. However, it has demonstrated strong protection against the original SARS-CoV-2 strain as well as certain other variants. Overall, it has achieved an efficacy rate of around 90% in clinical trials, which is almost on par with or surpasses some other approved COVID-19 vaccines.
  • Global impact
    Novavax has played a crucial role in addressing vaccine supply shortages in various countries. Its relatively straightforward manufacturing process may make it more accessible to regions with limited vaccine production and storage capabilities.
  • Booster potential
    Novavax’s technology may offer flexibility for developing boosters against emerging variants, as it allows for rapid adaptation of the vaccine to new spike protein sequences. This adaptability can be an advantage in the face of evolving viral strains.

Impact of Novavax vaccine on children’s health
Extensive clinical trials have confirmed the safety of the Novavax COVID-19 vaccine for adolescents aged 12 to 17. These trials include meticulous monitoring of side effects and adverse reactions, followed by rigorous data analysis to meet stringent safety standards. So, while Novavax, like all vaccines, may elicit side effects in some individuals, its severity may vary from one person to another. It’s also important to remember that even after a vaccine is allowed for use, scientists continue to monitor its efficacy carefully. This ongoing monitoring helps them to eliminate risks and improve the vaccine, making it even safer over time.

It’s important to note that the benefits of COVID-19 vaccination, including protection against severe illness, hospitalization, and death from COVID-19, generally outweigh the potential risks of side effects. It is crucial to consult with a healthcare provider if there are any concerns regarding the Novavax vaccine or its side effects. They can offer personalized information and guidance based on individual health, ensuring that one makes an informed decision. Additionally, one should keep in mind that information on vaccine safety can evolve over time, so it’s important to stay informed with the latest guidance and updates from health authorities.

Reference links:

https://www.yalemedicine.org/news/2019-novel-coronavirus

https://www.fda.gov/media/159902/download#:~:text=For%20the%20August%2019%2C%202022,phase%203%20trial%20described%20above.

https://www.yalemedicine.org/news/novavax-covid-vaccine 

https://www.yalemedicine.org/news/covid-19-vaccine-comparison

https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/different-types-of-covid-19-vaccines/art-20506465